active SUMO conjugation
inhibiting SUMO conjugation
efficient SUMO conjugation inhibitors
novel drugs
novel assay
oncogenic Myc
drug candidates
steps of drug development
Myc pathway
identification of novel therapeutic drugs
Myc-overexpressing cancers
drug discovery strategy
SUMOylation inhibitor
cancer types
Initial steps
non-oncogene addiction target of special relevance
proteins
Small Ubiquitin Modifier
high dependency
search
essential process
valorization
enterprise worth
involvement
eukaryotes
clinical studies
aspects of cell biology
identified product
key element
recent reports
neurodegenerative diseases
available commercialization opportunities
fact
patent
group
project
Defects
millions of people
main outcome
results